HomeCompareAVSFY vs JNJ

AVSFY vs JNJ: Dividend Comparison 2026

AVSFY yields 5.78% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 AVSFY wins by $14189.61M in total portfolio value
10 years
AVSFY
AVSFY
● Live price
5.78%
Share price
$25.00
Annual div
$1.45
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$14189.64M
Annual income
$13,733,327,166.79
Full AVSFY calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — AVSFY vs JNJ

📍 AVSFY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAVSFYJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, AVSFY + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
AVSFY pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AVSFY
Annual income on $10K today (after 15% tax)
$491.44/yr
After 10yr DRIP, annual income (after tax)
$11,673,328,091.77/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, AVSFY beats the other by $11,673,324,105.78/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AVSFY + JNJ for your $10,000?

AVSFY: 50%JNJ: 50%
100% JNJ50/50100% AVSFY
Portfolio after 10yr
$7094.83M
Annual income
$6,866,665,928.09/yr
Blended yield
96.78%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

AVSFY
No analyst data
Altman Z
9.5
Piotroski
6/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AVSFY buys
0
JNJ buys
8
PoliticianChamberTickerTypeAmountDate
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002026-01-23
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-12-18
Lloyd Doggett🏢 House$JNJ▲ Buy$1,001 - $15,0002025-12-09
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002025-11-20
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-11-13
Rich McCormick🏢 House$JNJ▲ Buy$1,001 - $15,0002025-11-05
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Jared Moskowitz🏢 House$JNJ▼ Sell$1,001 - $15,0002025-10-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAVSFYJNJ
Forward yield5.78%2.13%
Annual dividend / share$1.45$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%28%
Portfolio after 10y$14189.64M$30.3K
Annual income after 10y$13,733,327,166.79$4,689.40
Total dividends collected$14157.94M$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: AVSFY vs JNJ ($10,000, DRIP)

YearAVSFY PortfolioAVSFY Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$11,856$1,156.34$10,592$272.30+$1.3KAVSFY
2$15,249$2,562.60$11,289$357.73+$4.0KAVSFY
3$22,477$6,160.48$12,123$472.89+$10.4KAVSFY
4$41,023$16,972.93$13,141$629.86+$27.9KAVSFY
5$101,797$57,902.48$14,408$846.81+$87.4KAVSFY
6$377,489$268,565.91$16,021$1,151.60+$361.5KAVSFY
7$2,265,424$1,861,510.69$18,122$1,588.22+$2.25MAVSFY
8$23,305,279$20,881,275.93$20,930$2,228.20+$23.28MAVSFY
9$426,457,501$401,520,852.21$24,792$3,191.91+$426.43MAVSFY
10$14,189,636,693$13,733,327,166.79$30,274$4,689.40+$14189.61MAVSFY

AVSFY vs JNJ: Complete Analysis 2026

AVSFYStock

AVI Limited, together with its subsidiaries, manufactures, processes, markets, and distributes branded consumer products in the food, beverage, footwear, apparel, and cosmetics sectors in South Africa and internationally. It operates through Entyce Beverages, Snackworks, I&J, Personal Care, and Footwear & Apparel segments. The company provides hot beverages, such as tea, coffee, and creamer; sweet and savoury biscuits; baked and fried potato and maize snacks; frozen convenience foods; out-of-home ranges; personal care products, including body spray, fragrance, cosmetics, and body lotion products; footwear and accessories; and fashion apparels. It offers beverages under the Five Roses, Freshpak, Trinco, Ellis Brown, Frisco, House of Coffees, Koffiehuis, Ciro, and Lavazza brands; biscuits and snacks under the Bakers, Willards, Baker Street, and ProVita brands; frozen foods under the I&J brand; and personal care products under the Yardley and Lenthéric brands. The company also provides fashion products under the Spitz, Kurt Geiger, Lacoste, Carvela, Tosoni, Gant, Green Cross, and GX&Co brands. AVI Limited is based in Johannesburg, South Africa.

Full AVSFY Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this AVSFY vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AVSFY vs SCHDAVSFY vs JEPIAVSFY vs OAVSFY vs KOAVSFY vs MAINAVSFY vs ABBVAVSFY vs MRKAVSFY vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.